ClinicalTrials.gg

Vulvar Diseases clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 21 studies for Vulvar Diseases across more than 10 countries. 6 are recruiting or about to start. 7 of them are mainly about Vulvar Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-11. Counting its 6 narrower conditions too, such as Vulvar Neoplasms: 512 studies, 117 open.

Status

Completed
10
Recruiting
6
Terminated
2
Suspended
1
Active, not recruiting
1
Status unknown
1

Phase

Phase 2
5
Phase 1
4
Phase 4
1
Phase 3
1

Where

United States
13
United Kingdom
2
Denmark
2
Canada
2
Croatia
1
Spain
1

Who develops what

Add Vulvar Diseases to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 0 programs from 0 companies, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
IrinotecanRecent, limited
Evidence
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)11 study
DocetaxelRecent, limited
Evidence
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 0 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Vulvar Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

0phase 3 studies under way
3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Who these studies take

Of the 6 Vulvar Diseases studies recruiting now, 5 (83%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (17%) take children under 18. 5 (83%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 6
AgeWomenMen
101 (17%)0 (0%)
186 (100%)1 (17%)
306 (100%)1 (17%)
406 (100%)1 (17%)
506 (100%)1 (17%)
656 (100%)1 (17%)
756 (100%)1 (17%)
856 (100%)1 (17%)

Across all 21 studies, recruiting or not: 19% stop at 75 or younger and 19% at 65; 24% take children; 90% are for women only and 0% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. search them.